News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Industry Trends

>
  • IR Licensing and Partnerships

Latest News

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal
Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal
By Don Tracy, Associate Editor

May 19th 2025

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition
By Don Tracy, Associate Editor

May 16th 2025

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in its strategic plans amid recent market challenges.

Earned Media and ASCO: Provide Context Beyond the Data
Earned Media and ASCO: Provide Context Beyond the Data
By Michael Christel

May 13th 2025

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
By Don Tracy, Associate Editor

May 13th 2025

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D
Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D
By Don Tracy, Associate Editor

April 28th 2025

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

More News


Lisa Henderson thumbnail.jpg

Don’t Ignore These Trend ‘Leftovers’

Lisa Henderson
January 1st 2019

Highlighting a few topics that just missed the cut for our annual Industry Outlook-but are worth keeping a close eye on.


Biopharma Business Check

Biopharma Business Check

Peter Young
November 14th 2018

The increase in new drug approvals and candidates in development are good signs for pharma and biotech, but both sectors face continued pricing, cost, and healthcare policy-related challenges ahead.


Jill thumbnail.jpg

Attack Mounts on Biopharma Drug Prices

Jill Wechsler, Pharm Exec’s Washington Correspondent
November 10th 2018

Efforts intensify to bring outlays more in line with global trends.


Choosing the Right Track: Pharma & Healthcare MBAs

Choosing the Right Track: Pharma & Healthcare MBAs

Julian Upton
October 26th 2018

A growing range of MBAs with concentrations in pharmaceuticals and healthcare management are on offer. Pharm Exec look at how three of the top programs in the US prepare their students for industry success.


Pharm Exec's 17th Annual Industry Audit

Pharm Exec's 17th Annual Industry Audit

Bill Trombetta
September 12th 2018

Pharm Exec’s latest company leaderboard in delivering shareholder value highlights the most critical measure of management performance-return on invested capital.


Navigating the Increasing Complexity of Drug-Biomarker Co-Development

Navigating the Increasing Complexity of Drug-Biomarker Co-Development

Barry S. Sall, Angela X. Qu, MD, PhD
September 10th 2018

To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.


Pharm Exec’s 14th Annual Press Audit: The Opioid Crisis Takes Center Stage

Pharm Exec’s 14th Annual Press Audit: The Opioid Crisis Takes Center Stage

George Sillup and Stephen J. Porth
August 21st 2018

The opioid crisis dominated the news in this year’s annual audit of press coverage of the pharmaceutical industry. George P. Sillup and Stephen J. Porth report.


Cross-Border Funding in the Life Sciences

Cross-Border Funding in the Life Sciences

James Leech
August 21st 2018

Record capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.


Navigating the Complex Reimbursement and Policy Landscape of Healthcare Access

Navigating the Complex Reimbursement and Policy Landscape of Healthcare Access

Pharmaceutical Executive
August 13th 2018

Tommy Bramley and Kristine Flemister discuss today’s increasingly complex healthcare environment, and share insights into how stakeholders should be evolving to better help patients and providers navigate barriers around access and affordability.


The Key to Better Navigating VUCA Industry Conditions

The Key to Better Navigating VUCA Industry Conditions

Alison Horstmeyer
July 18th 2018

Alison Horstmeyer discusses how pharma executives can apply four attributes of curiosity to negotiate VUCA (volatile, uncertain, complex, and ambiguous) conditions and improve organizational outcomes.


US Maps Strategy to Reform Drug Pricing

US Maps Strategy to Reform Drug Pricing

Jill Wechsler, Pharm Exec’s Washington Correspondent
June 20th 2018

Azar and Gottlieb out front in revising rebates, restructuring Medicare, and promoting competition.


Can Trump Plan Serve as Model for What Ails Europe?

Can Trump Plan Serve as Model for What Ails Europe?

Reflector
June 18th 2018

Weighing the crossover effect of US’s new pricing blueprint. 


Midterm Elections PQ2.png

Piecing Together the Pricing Puzzle: The Midterm Elections

Sudip Parikh
June 10th 2018

There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.


Pharm Exec's Top 50 Companies 2018

Pharm Exec's Top 50 Companies 2018

Michael Christel
June 1st 2018

Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth in a potentially resurgent marketplace.


Site Logo

Building New York Into the Next Biotech Hotspot

Michelle Maskaly
May 22nd 2018

Known as the city that never sleeps, attracting and keeping the scientific breakthroughs in-state is something that’s keeping New York economic and academic developers up at night.


Site Logo

Gottlieb Tackles Drug Competition & Costs

Jill Wechsler, Pharm Exec’s Washington Correspondent
May 9th 2018

Pharm Exec interviews the FDA commissioner, who is building support by combating opioid abuse and advancing innovation.


Vaccines and AMR: Strengthening the Fight

Vaccines and AMR: Strengthening the Fight

Julian Upton
April 20th 2018

To coincide with World Immunization Week, IFPMA's Thomas Cueni, chair of the AMR Industry Alliance, outlines the critical importance of vaccines in the fight against AMR and infectious diseases.


Patient Adherence and Human Nature

Patient Adherence and Human Nature

Jim O’Donoghue
April 15th 2018

With less than 50% of patients with long-term conditions remaining adherent to their recommended treatment, we need to look to behavioral science to deconstruct the barriers that make people act in ways that can seem self-defeating, writes Jim O'Donaghue.


Planning for Post-Deal Integration

Planning for Post-Deal Integration

Jo Pisani and Cynthia Chan
April 10th 2018

Jo Pisani and Cynthia Chan outline the key legal considerations for post-deal integration.


Pricing Turning Point: The Case for Innovating Pharma’s Model

Pricing Turning Point: The Case for Innovating Pharma’s Model

Juan F. Rivera;Caitlyn Macdonald
March 6th 2018

Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.


Accentuate the Positive: Tackling Pharma’s Reputation Problem

Accentuate the Positive: Tackling Pharma’s Reputation Problem

Julian Upton
February 12th 2018

Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to its stakeholders-most importantly, patients and the wider public.


Pharma's Image Fix: Lessons from the Field

Pharma's Image Fix: Lessons from the Field

Lisa Henderson
February 12th 2018

Pharm Exec chronicles the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader-a C-suite must in reviving the industry’s beleaguered reputation.


Industry Engine Check

Industry Engine Check

Peter Young
February 2nd 2018

2017 was a year of swings and momentum for the pharma and biotech markets. Is more stable footing ahead?


Changing Skies: Pharm Exec’s 2018 Industry Forecast

Changing Skies: Pharm Exec’s 2018 Industry Forecast

Pharmaceutical Executive Editorial Staff
January 26th 2018

In our annual temperature check on the life sciences sector and its outlook for the months ahead, we explore eight trends that will shape the biopharma industry landscape in 2018.


Site Logo

Prices and Competition to Shape the Year Ahead

Jill Wechsler, Pharm Exec’s Washington Correspondent
January 11th 2018

States will continue to press for price controls, while FDA will tackle opioids and promote innovation.


Global Health: Fighting the Good Fight

Global Health: Fighting the Good Fight

Julian Upton
December 30th 2017

Pharm Exec details the latest approaches to combating disease and health crises on a global scale-including industry perspectives from those involved on the front lines.


Site Logo

Top Health Industry Issues Report from PwC

December 15th 2017


Global Health: Messages of Hope

Global Health: Messages of Hope

Michelle Maskaly
December 12th 2017

Figuring out the right formula to address global health-for the better.


Global Report PQ2.png

Will Europe Turn a Corner in Personalized Medicine?

Reflector
December 10th 2017

New action plan urges tighter alignment of public health policy with the development of targeted therapies.


New Targets for the Osteoporosis Market

New Targets for the Osteoporosis Market

Bagrat Lalayan
December 6th 2017

Bagrat Lalayan presents an overview of osteoporosis treatment market and offers vision for future business strategies.

<1
...
111213141516171819>
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.